The IGF2BP3 Knockout 143B Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human osteosarcoma 143B cell line. This product provides a mixed pool of cells with disrupted IGF2BP3 alleles, enabling loss-of-function studies without clonal selection bias and offering a robust model for experiments requiring large cell numbers, such as pooled screens or bulk biochemical assays.
The 143B cell line is a highly metastatic osteosarcoma model, originally derived as a TK- variant of the HOS cell line. It is characterized by an activating KRAS mutation and deficiencies in the tumor suppressors p53 and Rb, which contribute to its aggressive behavior and frequent use in metastasis research, particularly for studying lung colonization and therapeutic resistance.
IGF2BP3 is an oncofetal RNA-binding protein that post-transcriptionally regulates gene expression by binding to the 3?? untranslated regions of target mRNAs, including MYC, CCND1, CD44, and ACTB, thereby stabilizing these transcripts and enhancing their translation. Its activity is regulated by upstream factors such as MYC, Wnt/??-catenin, and hypoxia-induced HIF1A. IGF2BP3 forms complexes with components of the translation initiation machinery, such as EIF4E and PABPC1, as well as ribosomal subunits, and interacts with other RNA-binding proteins like FMR1 and HNRNPA2B1. These molecular interactions reinforce oncogenic signaling through the PI3K/AKT, MAPK, and Wnt/??-catenin pathways, ultimately promoting cellular proliferation, migration, and invasion.
In the 143B osteosarcoma background, disruption of IGF2BP3 is expected to downregulate critical targets such as MYC and CCND1, leading to reduced proliferative and invasive capacities. This knockout model is therefore a valuable tool for investigating the role of post-transcriptional mRNA stabilization in osteosarcoma aggressiveness and for examining how metastatic traits depend on IGF2BP3 activity. It provides a relevant genetic context for comparative studies between parental and knockout cells.
This product is well-suited for a range of research applications, including the study of RNA-based regulatory mechanisms in cancer, elucidation of molecular pathways driving osteosarcoma metastasis, and screening of small-molecule inhibitors targeting IGF2BP3. Compatible experimental techniques include western blotting, RT-qPCR, RNA immunoprecipitation, RNA stability assays, migration and invasion assays, cell proliferation assays, and luciferase reporter assays. For further information, please contact Ascent Research.
